MX2022012295A - Celulas b modificadas y metodos de uso de las mismas. - Google Patents

Celulas b modificadas y metodos de uso de las mismas.

Info

Publication number
MX2022012295A
MX2022012295A MX2022012295A MX2022012295A MX2022012295A MX 2022012295 A MX2022012295 A MX 2022012295A MX 2022012295 A MX2022012295 A MX 2022012295A MX 2022012295 A MX2022012295 A MX 2022012295A MX 2022012295 A MX2022012295 A MX 2022012295A
Authority
MX
Mexico
Prior art keywords
cell
payload
modified
domain
cells
Prior art date
Application number
MX2022012295A
Other languages
English (en)
Inventor
Mark Selby
Thomas Brennan
Hangil Park
Kathleen Boyle
Srinivas Kothakota
Lewis T Williams
Original Assignee
Walking Fish Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walking Fish Therapeutics filed Critical Walking Fish Therapeutics
Publication of MX2022012295A publication Critical patent/MX2022012295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a células B modificadas genéticamente y usos de las mismas, por ejemplo, para el tratamiento de una variedad de enfermedades y trastornos, incluyendo cáncer, enfermedades cardíacas, enfermedades inflamatorias, atrofia muscular, enfermedades neurológicas y similares. En ciertas modalidades, la invención se relaciona con una célula B modificada aislada ("célula CAR-B"), capaz de expresar un receptor quimérico ("receptor CAR-B"), en donde el receptor quimérico comprende (a) un dominio extracelular; (b) un dominio de transmembrana; y (c) un dominio citoplasmático que comprende al menos un dominio de señalización. En diversas modalidades, la invención comprende una célula B modificada aislada, en donde la célula B es capaz de expresar y secretar una carga útil, en donde la carga útil no se expresa naturalmente en una célula B o se expresa en niveles más altos que los que se expresan naturalmente en una B célula. En diversas modalidades, la carga útil es un anticuerpo o un fragmento del mismo.
MX2022012295A 2020-03-31 2021-03-31 Celulas b modificadas y metodos de uso de las mismas. MX2022012295A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003120P 2020-03-31 2020-03-31
PCT/US2021/025273 WO2021202810A2 (en) 2020-03-31 2021-03-31 Modified b cells and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022012295A true MX2022012295A (es) 2023-03-06

Family

ID=77930050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012295A MX2022012295A (es) 2020-03-31 2021-03-31 Celulas b modificadas y metodos de uso de las mismas.

Country Status (10)

Country Link
JP (1) JP2023521966A (es)
KR (1) KR20230006821A (es)
CN (1) CN115552017A (es)
AU (1) AU2021249123A1 (es)
BR (1) BR112022019797A2 (es)
CA (1) CA3173480A1 (es)
CL (1) CL2022002667A1 (es)
IL (1) IL296947A (es)
MX (1) MX2022012295A (es)
WO (1) WO2021202810A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768707A4 (en) * 2018-03-19 2022-01-26 The Invention Science Fund II, LLC COMPOSITIONS AND METHODS FOR MODIFIED B LYMPHOCYTES EXPRESSING REASSIGNED BIOLOGICAL AGENTS
US11864683B2 (en) 2020-06-24 2024-01-09 Kalenian Coffee Consulting LLC Methods for producing liquid extracts
CN116829160A (zh) * 2020-09-02 2023-09-29 步行鱼治疗学股份有限公司 经修饰的b细胞及其使用方法
CN116426483B (zh) * 2021-12-30 2024-02-23 南京紫珑生物科技有限公司 Cd258蛋白在免疫治疗中的应用
WO2023152752A1 (en) * 2022-02-14 2023-08-17 Ramot At Tel-Aviv University Ltd. Genetic engineering of b cells and uses thereof in antigen-induced therapeutic protein secretion
KR20250027596A (ko) * 2022-03-09 2025-02-26 다나-파버 캔서 인스티튜트 인크. 유전자 조작된 b 세포 및 이의 사용 방법
WO2024196669A2 (en) * 2023-03-17 2024-09-26 Walking Fish Therapeutics, Inc. Methods for in vivo editing of b cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0225279D0 (en) * 2002-10-30 2002-12-11 Celltech R&D Ltd Biological products
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CN118185874A (zh) * 2016-04-04 2024-06-14 苏黎世联邦理工学院 一种重组哺乳动物b细胞
WO2017214376A1 (en) * 2016-06-10 2017-12-14 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
ES2912269T3 (es) * 2016-09-27 2022-05-25 Cero Therapeutics Inc Moléculas de receptor de engullimiento quimérico
AU2018258045B2 (en) * 2017-04-26 2024-02-29 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
CA3073421A1 (en) * 2017-09-26 2019-04-04 Daniel Mark COREY Chimeric engulfment receptor molecules and methods of use

Also Published As

Publication number Publication date
KR20230006821A (ko) 2023-01-11
WO2021202810A3 (en) 2021-11-11
CA3173480A1 (en) 2021-10-07
BR112022019797A2 (pt) 2022-12-13
CN115552017A (zh) 2022-12-30
JP2023521966A (ja) 2023-05-26
IL296947A (en) 2022-12-01
CL2022002667A1 (es) 2023-09-22
WO2021202810A2 (en) 2021-10-07
AU2021249123A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
MX2022012295A (es) Celulas b modificadas y metodos de uso de las mismas.
ZA202211593B (en) Modified b cells and methods of use thereof
Yin et al. Pathogenesis of epilepsy: challenges in animal models
CL2022003796A1 (es) Receptores antigénicos quiméricos con especificidad para bcma y usos de estos
CL2019002324A1 (es) Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerización de fijación a nucleótidos p3 (nlrp3).
MX2012002927A (es) Anticuerpos humanos de alta afinidad con el receptor activado por proteasa humana-2.
BR112022008633A2 (pt) Terapia de células car-t direcionadas a bcma de mieloma múltiplo
AR080154A1 (es) Anticuerpos cd20 y su utilizacion
CL2023000602A1 (es) Células b modificadas y métodos de uso de las mismas
AR080026A1 (es) Metodos de tratamiento de enfermedades autoinmunitarias con antagonistas del ligando 4 similar a delta (dll4)
CO2020014681A2 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
MX2025011926A (es) Metodos para tratamiento de enfermedades autoinmunitarias
AR071146A1 (es) Inhibicion relacionada con arni de la via de senales tnf alfa para el tratamiento de angiogenesis ocular, uso de una molecula de arn de interferencia y molecula de arn de interferencia
Lavagnino et al. High magnitude, in vitro, biaxial, cyclic tensile strain induces actin depolymerization in tendon cells
Prasad et al. A study of middle ear reconstruction, the degree of functional restoration and causes of graft failure following chronic ear disease
Gupta et al. Bile Canaliculi Contractility Is Regulated by Canalicular Pressure Sensing via PIEZO1
Agarwal et al. Silicone & Science: How Menstrual Cups Reshaped Period Health
Du Toit et al. SOMATIC-CELL NUCLEAR TRANSFER: AUTOLOGOUS EMBRYONIC INTRA-SPINAL STEM CELL TRANSPLANT IN A CHRONIC COMPLETE QUADRIPLEGIC PATIENT. NEURO-ANATOMICAL OUTCOME AFTER ONE YEAR. Transferencia de núcleos de células madre: Transplante embriónico autólogo intraesp
CL2024003820A1 (es) Proteínas de fusión que comprenden un agonista mejorado del receptor glp-1 y sus usos
Puppo et al. GP 12: Molecular defects in FAT1 are associated to facioscapulohumeral dystrophy (FSHD)
Atamanova Specific features of higher mental functioning in post-stroke patients
Atamanova The relationship between poststroke patients’ quality of life and brain lesion localization
Epro et al. Achilles tendon is mechanosensitive in old adults: a 1.5 year resistance training intervention
Dwijayanti et al. Brain derived neurotrophic factor levels in aged rats post-systemic human mesenchymal stem cell administration
Šinkūnaitė et al. CHANGES OF CUTANEOUS AND CORTICAL SILENT RESPONSES IN A RANDOM SAMPLE OF LITHUANIA PATIENTS WITH PARKINSON DISEASE.